Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Foghorn Therapeutics Inc. stock logo
FHTX
Foghorn Therapeutics
$5.77
+7.1%
$5.37
$2.94
$10.25
$326.18M3.0578,611 shs110,354 shs
Lifecore Biomedical, Inc. stock logo
LFCR
Lifecore Biomedical
$7.53
-5.2%
$7.62
$4.33
$8.85
$281.68M0.64106,325 shs138,549 shs
Repare Therapeutics Inc. stock logo
RPTX
Repare Therapeutics
$1.69
$1.55
$0.89
$4.07
$72.60M0.9488,692 shs47,237 shs
Tvardi Therapeutics, Inc. stock logo
TVRD
Tvardi Therapeutics
$31.11
+2.2%
$25.80
$8.13
$34.31
$291.73M0.2519,544 shs13,827 shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Foghorn Therapeutics Inc. stock logo
FHTX
Foghorn Therapeutics
+7.05%+14.03%+17.76%+29.37%-27.60%
Lifecore Biomedical, Inc. stock logo
LFCR
Lifecore Biomedical
-5.16%-1.05%-2.59%+9.93%+78.44%
Repare Therapeutics Inc. stock logo
RPTX
Repare Therapeutics
0.00%+1.20%+10.46%+14.97%-38.99%
Tvardi Therapeutics, Inc. stock logo
TVRD
Tvardi Therapeutics
+2.20%+3.98%+28.87%+9.16%+3,110,999,900.00%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Foghorn Therapeutics Inc. stock logo
FHTX
Foghorn Therapeutics
$5.77
+7.1%
$5.37
$2.94
$10.25
$326.18M3.0578,611 shs110,354 shs
Lifecore Biomedical, Inc. stock logo
LFCR
Lifecore Biomedical
$7.53
-5.2%
$7.62
$4.33
$8.85
$281.68M0.64106,325 shs138,549 shs
Repare Therapeutics Inc. stock logo
RPTX
Repare Therapeutics
$1.69
$1.55
$0.89
$4.07
$72.60M0.9488,692 shs47,237 shs
Tvardi Therapeutics, Inc. stock logo
TVRD
Tvardi Therapeutics
$31.11
+2.2%
$25.80
$8.13
$34.31
$291.73M0.2519,544 shs13,827 shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Foghorn Therapeutics Inc. stock logo
FHTX
Foghorn Therapeutics
+7.05%+14.03%+17.76%+29.37%-27.60%
Lifecore Biomedical, Inc. stock logo
LFCR
Lifecore Biomedical
-5.16%-1.05%-2.59%+9.93%+78.44%
Repare Therapeutics Inc. stock logo
RPTX
Repare Therapeutics
0.00%+1.20%+10.46%+14.97%-38.99%
Tvardi Therapeutics, Inc. stock logo
TVRD
Tvardi Therapeutics
+2.20%+3.98%+28.87%+9.16%+3,110,999,900.00%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Foghorn Therapeutics Inc. stock logo
FHTX
Foghorn Therapeutics
3.17
Buy$10.6784.86% Upside
Lifecore Biomedical, Inc. stock logo
LFCR
Lifecore Biomedical
2.50
Moderate Buy$8.006.24% Upside
Repare Therapeutics Inc. stock logo
RPTX
Repare Therapeutics
2.50
Moderate Buy$4.50166.27% Upside
Tvardi Therapeutics, Inc. stock logo
TVRD
Tvardi Therapeutics
3.00
Buy$64.25106.53% Upside

Current Analyst Ratings Breakdown

Latest RPTX, FHTX, LFCR, and TVRD Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/3/2025
Lifecore Biomedical, Inc. stock logo
LFCR
Lifecore Biomedical
KeyCorp
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageSector Weight
7/14/2025
Tvardi Therapeutics, Inc. stock logo
TVRD
Tvardi Therapeutics
Raymond James Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageOutperform$62.00
7/11/2025
Tvardi Therapeutics, Inc. stock logo
TVRD
Tvardi Therapeutics
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageOverweight$52.00
6/12/2025
Tvardi Therapeutics, Inc. stock logo
TVRD
Tvardi Therapeutics
Piper Sandler
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageOverweight$78.00
(Data available from 9/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Foghorn Therapeutics Inc. stock logo
FHTX
Foghorn Therapeutics
$22.60M14.43N/AN/A($0.82) per share-7.04
Lifecore Biomedical, Inc. stock logo
LFCR
Lifecore Biomedical
$128.87M2.19N/AN/A$0.04 per share188.25
Repare Therapeutics Inc. stock logo
RPTX
Repare Therapeutics
$53.48M1.36N/AN/A$3.56 per share0.47
Tvardi Therapeutics, Inc. stock logo
TVRD
Tvardi Therapeutics
$7.14M40.87N/AN/A($3.02) per share-10.30
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Foghorn Therapeutics Inc. stock logo
FHTX
Foghorn Therapeutics
-$86.62M-$1.19N/AN/AN/A-311.90%N/A-28.00%11/3/2025 (Estimated)
Lifecore Biomedical, Inc. stock logo
LFCR
Lifecore Biomedical
-$38.72M-$1.31N/AN/AN/A-31.70%-846.51%-13.03%10/3/2025 (Estimated)
Repare Therapeutics Inc. stock logo
RPTX
Repare Therapeutics
-$84.69M-$2.58N/AN/AN/AN/A-78.25%-66.85%11/6/2025 (Estimated)
Tvardi Therapeutics, Inc. stock logo
TVRD
Tvardi Therapeutics
-$70.87MN/A0.00N/A-678.79%-565.83%-66.71%N/A

Latest RPTX, FHTX, LFCR, and TVRD Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
10/3/2025Q1 2026
Lifecore Biomedical, Inc. stock logo
LFCR
Lifecore Biomedical
-$0.29N/AN/AN/A$26.68 millionN/A
8/14/2025Q2 2025
Tvardi Therapeutics, Inc. stock logo
TVRD
Tvardi Therapeutics
-$0.51-$1.00-$0.49-$1.00N/AN/A
8/8/2025Q2 2025
Repare Therapeutics Inc. stock logo
RPTX
Repare Therapeutics
-$0.56-$0.39+$0.17-$0.39$2.50 million$0.25 million
8/7/2025Q4 2025
Lifecore Biomedical, Inc. stock logo
LFCR
Lifecore Biomedical
-$0.09-$0.10-$0.01-$0.06$35.36 million$36.44 million
8/5/2025Q2 2025
Foghorn Therapeutics Inc. stock logo
FHTX
Foghorn Therapeutics
-$0.31-$0.28+$0.03-$0.28$7.62 million$7.56 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Foghorn Therapeutics Inc. stock logo
FHTX
Foghorn Therapeutics
N/AN/AN/AN/AN/A
Lifecore Biomedical, Inc. stock logo
LFCR
Lifecore Biomedical
N/AN/AN/AN/AN/A
Repare Therapeutics Inc. stock logo
RPTX
Repare Therapeutics
N/AN/AN/AN/AN/A
Tvardi Therapeutics, Inc. stock logo
TVRD
Tvardi Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Foghorn Therapeutics Inc. stock logo
FHTX
Foghorn Therapeutics
N/A
2.62
2.62
Lifecore Biomedical, Inc. stock logo
LFCR
Lifecore Biomedical
113.76
2.84
1.77
Repare Therapeutics Inc. stock logo
RPTX
Repare Therapeutics
N/A
6.30
6.30
Tvardi Therapeutics, Inc. stock logo
TVRD
Tvardi Therapeutics
N/A
4.04
4.04

Institutional Ownership

CompanyInstitutional Ownership
Foghorn Therapeutics Inc. stock logo
FHTX
Foghorn Therapeutics
61.55%
Lifecore Biomedical, Inc. stock logo
LFCR
Lifecore Biomedical
83.36%
Repare Therapeutics Inc. stock logo
RPTX
Repare Therapeutics
85.09%
Tvardi Therapeutics, Inc. stock logo
TVRD
Tvardi Therapeutics
44.66%

Insider Ownership

CompanyInsider Ownership
Foghorn Therapeutics Inc. stock logo
FHTX
Foghorn Therapeutics
7.58%
Lifecore Biomedical, Inc. stock logo
LFCR
Lifecore Biomedical
32.20%
Repare Therapeutics Inc. stock logo
RPTX
Repare Therapeutics
11.50%
Tvardi Therapeutics, Inc. stock logo
TVRD
Tvardi Therapeutics
3.10%
CompanyEmployeesShares OutstandingFree FloatOptionable
Foghorn Therapeutics Inc. stock logo
FHTX
Foghorn Therapeutics
12056.53 million52.25 millionOptionable
Lifecore Biomedical, Inc. stock logo
LFCR
Lifecore Biomedical
69037.41 million25.36 millionOptionable
Repare Therapeutics Inc. stock logo
RPTX
Repare Therapeutics
18042.96 million38.02 millionOptionable
Tvardi Therapeutics, Inc. stock logo
TVRD
Tvardi Therapeutics
809.38 million9.09 millionN/A

Recent News About These Companies

Tvardi: Q2 Earnings Snapshot
TVRD Tvardi Therapeutics, Inc.
Tvardi Therapeutics Inc (TVRD)

New MarketBeat Followers Over Time

Media Sentiment Over Time

Foghorn Therapeutics stock logo

Foghorn Therapeutics NASDAQ:FHTX

$5.77 +0.38 (+7.05%)
Closing price 09/5/2025 04:00 PM Eastern
Extended Trading
$5.78 +0.01 (+0.09%)
As of 09/5/2025 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It develops FHD-286, a small molecule inhibitor of the enzymatic activity of BRG1 and BRM that is in phase I for the treatment of relapsed and/or refractory acute myeloid leukemia/myelodysplastic syndrome. The company is also developing therapies for mutant cancers, such as Non-Small Cell Lung, bladder, endometrial, colorectal, and melanoma cancers; and dependent cancers, including prostate cancer and diffuse large b-cell lymphoma. It has a research collaboration and license agreement with Merck Sharp & Dohme Corp. to discover and develop novel oncology therapeutics against a transcription factor target; and Eli Lilly and Company for developing FHD-909, a selective ATPase inhibitor of BRM. Foghorn Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Lifecore Biomedical stock logo

Lifecore Biomedical NASDAQ:LFCR

$7.53 -0.41 (-5.16%)
Closing price 09/5/2025 04:00 PM Eastern
Extended Trading
$7.54 +0.01 (+0.20%)
As of 09/5/2025 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. The company engages in the manufacturing of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures. It also provides services, such as technology development, material component changes, analytical method development, formulation development, pilot studies, stability studies, process validation, and production of materials for clinical studies to its partners for HA-based and non-HA based aseptically formulated and filled products. The company was formerly known as Landec Corporation and changed its name to Lifecore Biomedical, Inc. in November 2022. Lifecore Biomedical, Inc. was founded in 1965 and is headquartered in Chaska, Minnesota.

Repare Therapeutics stock logo

Repare Therapeutics NASDAQ:RPTX

$1.69 0.00 (0.00%)
Closing price 09/5/2025 04:00 PM Eastern
Extended Trading
$1.72 +0.03 (+1.48%)
As of 09/5/2025 06:52 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Repare Therapeutics Inc., a clinical-stage precision oncology company, engages in the discovery and development of therapeutics by using its synthetic lethality approach in Canada and the United States. It uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform, to discover, validate, and build a pipeline of SL-based therapeutics that focuses on genomic instability, including DNA damage repair. The company's lead product candidate is Camonsertib (RP-3500), an oral small molecule inhibitor under Phase ½ development for the treatment of solid tumors with specific DNA damage repair-related genomic alterations. It is also developing Lunresertib (RP-6306), a PKMYT1 Inhibitor, which is under Phase 1 clinical trial for tumors with genetic alterations characterized by CCNE1 amplification; RP-1664, an oral PLK4 inhibitor, under Phase 1 clinical trial designed to harness the synthetic lethal relationship with TRIM37 amplification or overexpression in solid tumors; and RP-3467, a polymerase theta adenosinetriphosphatase (ATPase) inhibitor, a SL target associated with BRCA mutations and other genomic alterations. The company has license and collaboration agreement with Hoffmann-La Roche Inc. and F. Hoffmann-La Roche Ltd; Bristol-Myers Squibb Company; New York University; and Ono Pharmaceutical Co., as well as a clinical study and collaboration agreement with Debiopharm to explore the synthetic lethal combination of PKMYT1 and WEE1 inhibition in cancer. Repare Therapeutics Inc. was incorporated in 2016 and is headquartered in Montréal, Canada.

Tvardi Therapeutics stock logo

Tvardi Therapeutics NASDAQ:TVRD

$31.11 +0.67 (+2.20%)
As of 09/5/2025 04:00 PM Eastern

Cara Therapeutics, Inc., an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. Its product candidate includes Oral KORSUVA (difelikefalin), which has completed Phase II clinical trial to treat pruritus atopic dermatitis and pruritus non-dialysis-dependent chronic kidney disease (NDD-CKD) associated pruritus; and in Phase II clinical trial to treat pruritus chronic liver disease (CLD) primary biliary cholangitis (PBC) and notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut.